# Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

> **NCT04915768** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 51 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** CH505 TF chTrimer
- **BIOLOGICAL:** 3M-05-AF
- **BIOLOGICAL:** Aluminum hydroxide suspension
- **BIOLOGICAL:** 3M-05-AF
- **BIOLOGICAL:** CH505 TF chTrimer

## Key facts

- **NCT ID:** NCT04915768
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-23
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915768, "Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04915768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*